Table 1 Summary and findings of neoadjuvant chemotherapy trials

1

Paclitaxel weekly and FAC

25% (breast and lymph nodes)

32

Docetaxel 100 mg/m² q 3 weeks × 4

0%

33

Doxorubicin 75 mg/m² × 3; then docetaxel 40 mg/m² q week × 6

12.5%

34

Doxyfluoridine 800 mg/m² D1-14; docetaxel 60 mg/m² D8 q 3 weeks

14%

35

Paclitaxel doxorubicin standard or DD × 6

ER^- 26%

ER⁺ 8%

37

Paclitaxel + doxorubicin × 4 then CMF × 4

23%

80

Epirubicin 120 mg/m² q 3 weeks ± tamoxifen

ER^- 23.4%

ER⁺ 4.6%

83

Vinorelbine 25 mg/m² D1 + 8 and epirubicin 60 mg/m² D1 versus AC × 6

15% both arms

85

TAC × 2: then PR to TAC × 6 (107 patients)

19%

<PR to TAC × 4 (24 patients) or vinorelbine and xeloda × 4 (20 patients)

26% for clinical responders to TAC

86

Vinorelbine/herceptin

29%

cCR+PR 93%

107

Epirubicin 60 mg/m² D1, CDDP 60 mg/m² D1, xeloda 1000 mg/m² BD D1-14

27%

131

Docetaxel 60 mg/m² + vinorelbine 45 mg/m² q 2 weeks + GCSF + herceptin in HER2⁺

36%

140

Gemcitabine 1 g/m², epirubicin 90 mg/ m², paclitaxel 175 mg/m² q 3 weeks

22.7%

143

Docetaxel 100 mg/m² q 3 weeks × 4

10%

160

Anthracycline SD or PD; 5FU 500 mg/m²/w + gemcitabine 100 mg/m²/w + dexamethasone 16 mg throughout radiotherapy (50 Gy +10 Gy boost)

28%

MRD (+pN0) 23%

163

Docetaxel 75 mg/m² + doxorubicin 50 mg/m² + cyclophosphamide 500 mg/m² × 4 q 3 weeks

8%

190

Docetaxel 100 mg/m² q 3 weeks × 6

19.8%